The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

2020/01/21 by Biswajit Chowdhury, Albert Z. Luu, Vincent Z. Luu +12 · 26 citations
Medicine · #Pulmonary Hypertension Research and Treatments #Heart Failure Treatment and Management #Peptidase Inhibition and Analysis

paper · doi:10.1016/j.bbrc.2020.01.015

Cited by

• Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
• Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. [europepmc]
• Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. [europepmc]
• Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors. [europepmc]
• Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. [europepmc]
• Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure. [europepmc]
• Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension. [europepmc]
• Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. [europepmc]
• Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. [europepmc]
• Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. [europepmc]
• Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction. [europepmc]
• Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. [europepmc]
• Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. [europepmc]
• Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. [europepmc]
• Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension. [europepmc]
• Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat. [europepmc]
• Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. [europepmc]
• Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis. [europepmc]
• Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. [europepmc]
• Heart failure in systemic right ventricle: Mechanisms and therapeutic options. [europepmc]
• The right ventricle in tetralogy of Fallot: adaptation to sequential loading. [europepmc]
• Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy. [europepmc]
• Effects of empagliflozin on right ventricular adaptation to pressure overload. [europepmc]
• Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation. [europepmc]
• Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review). [europepmc]
• Complement Immune System in Pulmonary Hypertension-Cooperating Roles of Circadian Rhythmicity in Complement-Mediated Vascular Pathology. [europepmc]